BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 35567547)

  • 1. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Murai H; Kodama T; Maesaka K; Tange S; Motooka D; Suzuki Y; Shigematsu Y; Inamura K; Mise Y; Saiura A; Ono Y; Takahashi Y; Kawasaki Y; Iino S; Kobayashi S; Idogawa M; Tokino T; Hashidate-Yoshida T; Shindou H; Miyazaki M; Imai Y; Tanaka S; Mita E; Ohkawa K; Hikita H; Sakamori R; Tatsumi T; Eguchi H; Morii E; Takehara T
    Hepatology; 2023 Jan; 77(1):77-91. PubMed ID: 35567547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
    Barsch M; Salié H; Schlaak AE; Zhang Z; Hess M; Mayer LS; Tauber C; Otto-Mora P; Ohtani T; Nilsson T; Wischer L; Winkler F; Manne S; Rech A; Schmitt-Graeff A; Bronsert P; Hofmann M; Neumann-Haefelin C; Boettler T; Fichtner-Feigl S; van Boemmel F; Berg T; Rimassa L; Di Tommaso L; Saeed A; D'Alessio A; Pinato DJ; Bettinger D; Binder H; John Wherry E; Schultheiss M; Thimme R; Bengsch B
    J Hepatol; 2022 Aug; 77(2):397-409. PubMed ID: 35367533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
    Weng J; Liu S; Zhou Q; Xu W; Xu M; Gao D; Shen Y; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
    Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
    J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy.
    Peng Q; Li S; Shi X; Guo Y; Hao L; Zhang Z; Ji J; Zhao Y; Li C; Xue Y; Liu Y
    Phytother Res; 2023 May; 37(5):1740-1753. PubMed ID: 36576358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.
    Liu L; Zhang R; Deng J; Dai X; Zhu X; Fu Q; Zhang H; Tong Z; Zhao P; Fang W; Zheng Y; Bao X
    Cancer Immunol Immunother; 2022 Jan; 71(1):121-136. PubMed ID: 34028567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic inflammatory IgA
    Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
    Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
    BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified immune cell infiltration score achieves ideal stratification for CD8
    Pan B; Luo Y; Ye D; Qiu J; Zhang X; Wu X; Yao Y; Wang X; Tang N
    Cancer Immunol Immunother; 2023 Dec; 72(12):4103-4119. PubMed ID: 37755466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.